Management of biofilm infections relies on time-consuming laboratory techniques and monitoring treatment by subjective clinical evaluations. Due to these limitations, there is a need to explore alternative strategies. The aims of this study were to assess the feasibility of using volatile organic compound (VOC) biomarkers to monitor treatment response and measure anti-biofilm efficacy of electrical stimulation (ES) in vitro and in human cutaneous wound biofilm models. Staphylococcus aureus (MSSA) and Pseudomonas aeruginosa (PA) biofilms were exposed to ES, ciprofloxacin, or both, with efficacy assessed and quantified by fluorescence staining, enumeration, metabolic assays, and biomass quantification; VOCs were measured by gas chromatography-mass spectrometry. In vitro MSSA and PA and ex vivo PA biofilms exposed to ES showed significantly reduced bacterial viability, metabolic activity, and biomass compared to controls (p < 0.05). There was significant variation in the relative abundance of VOCs in in vitro MSSA and PA and in ex vivo PA biofilms exposed to ES and antibiotic (p < 0.05). 2-methyl-1-propanol was associated with MSSA viability (R = 0.93, p < 0.05), biomass (R = 0.97, p < 0.05), and metabolic activity (R = 0.93, p < 0.05) and 3-methyl-1-butanol was associated with PA biomass (R = 0.93, p < 0.05). We showed that ES and VOC biomarkers are possible options for alternative nonpharmacological antimicrobial management of biofilms and noninvasive monitoring of wound infection treatment responses, respectively.
ABSTRACT
Management of biofilm infections relies on time-consuming laboratory techniques and monitoring treatment by subjective clinical evaluations. Due to these limitations, there is a need to explore alternative strategies. The aims of this study were to assess the feasibility of using volatile organic compound (VOC) biomarkers to monitor treatment response and measure anti-biofilm efficacy of electrical stimulation (ES) in vitro and in human cutaneous wound biofilm models. Staphylococcus aureus (MSSA) and Pseudomonas aeruginosa (PA) biofilms were exposed to ES, ciprofloxacin, or both, with efficacy assessed and quantified by fluorescence staining, enumeration, metabolic assays, and biomass quantification; VOCs were measured by gas chromatography-mass spectrometry. In vitro MSSA and PA and ex vivo PA biofilms exposed to ES showed significantly reduced bacterial viability, metabolic activity, and biomass compared to controls (p < 0.05). There was significant variation in the relative abundance of VOCs in in vitro MSSA and PA and in ex vivo PA biofilms exposed to ES and antibiotic (p < 0.05). 2-methyl-1-propanol was associated with MSSA viability (R = 0.93, p < 0.05), biomass (R = 0.97, p < 0.05), and metabolic activity (R = 0.93, p < 0.05) and 3-methyl-1-butanol was associated with PA biomass (R = 0.93, p < 0.05). We showed that ES and VOC biomarkers are possible options for alternative nonpharmacological antimicrobial management of biofilms and noninvasive monitoring of wound infection treatment responses, respectively.
Biofilms are major contributors to delayed cutaneous wound healing, constituting 60% of chronic wounds and up to 80% of surgical site infections (SSIs).
1,2 Current anti-biofilm management relies heavily on antibiotics 3 ; however, due to the occurrence and spread of antibiotic-resistant bacteria, there is a growing need for alternative treatment methods. 4 Also of concern is monitoring the treatment response which currently relies on subjective clinical evaluations, and objective laboratory techniques, such as culturing and sequencing. Clinical evaluation is heavily influenced by clinician variability and laboratory techniques are time consuming and resource dependent. 5, 6 Therefore, there is an urgent need to investigate the monitoring and treatment of wound biofilms. A significant limiting factor is the availability of appropriate models of chronic wound biofilm infections using skin. 7 There is accumulating research in the use of volatile organic compounds (VOCs) to diagnose diseases and infections. 8, 9 However, their use as biomarkers in monitoring disease progression and therapy efficacy is limited mainly to respiratory diseases and infections. 10 The use of electrical stimulation (ES) to treat chronic wounds is currently utilized in clinical wound care management [11] [12] [13] and recent reviews have clearly highlighted its beneficial 14, 15 Although the antimicrobial effects of ES are well-documented in vitro 16 and animal studies, 17 its efficacy against cutaneous wound biofilms is sparse. 18 The porcine model is the most common ex vivo skin/wound substrate used to study biofilm formation. [19] [20] [21] [22] [23] Anatomically and physiologically, pig skin is similar to human skin, 24 however it is not identical, leading to possible discrepancies when translating findings into clinical practice. Therefore, it is necessary to develop human skin models to emulate clinical conditions to allow meaningful interpretations of experimental findings. 25 Therefore, the threefold aims of this study were to assess the feasibility of using VOC biomarkers to monitor treatment response against cutaneous wound biofilms; to assess the antimicrobial efficacy of ES in a clinically relevant human cutaneous wound biofilm model; and finally, to use this model to validate the use of VOCs in assessing wound infections.
MATERIALS AND METHODS

Study design
Bacterial biofilms were grown on plastic coverslips and excisional human cutaneous wound tissue explants in broth medium at 37 C for 1 or 3 days. Pregrown biofilms were exposed to ES, antibiotics, or ES followed by antibiotic exposure. Five methods were used to evaluate the effects of treatments on biofilms. Biofilm visualization was by wide-field, bright-field, and fluorescence microscopy of multiply-stained sections. Biofilm viability was determined quantitatively by enumeration and fluorescent live/dead staining. The XTT cell proliferation assay was used to determine biofilm metabolism and the amount of double stranded DNA reflected biofilm biomass. 26 VOCs were identified using gas chromatographymass spectrometry (GCMS). All in vitro experiments were done twice in triplicate and all ex vivo experiments were done four times in triplicates (Figure 1 ).
Bacterial strains
Bacterial isolates were American Type Culture Collection reference strains obtained from LGC Standards (Teddington, UK). The bacterial strains used in this study were Staphylococcus aureus ATCC 29213 (MSSA) which is a methicillinsensitive wound isolate and Pseudomonas aeruginosa ATCC 27316 (PA) which is a human wound isolate. All strain stocks were frozen and stored long term at −80 C. All isolates were revived from frozen stocks onto Columbia agar containing horse blood (E&O Laboratories Ltd., Bonnybridge, Scotland) and incubated at 37 C for 16-18 hours prior to use.
Ex vivo cutaneous excisional wound organ culture models
Full thickness cutaneous tissue was obtained from human patients (n = 2; two female; mean age 40 years) undergoing elective surgery (one abdominoplasty; one breast reduction) with appropriate ethical approval. The skin underwent intraoperative disinfection with 0.5% (v/v) aqueous chlorhexidine. Tissue was trimmed of excess adipose tissue and disinfected with 2% (v/v) chlorhexidine gluconate and 70% (v/v) isopropyl alcohol (ChloraPrep Sepp applicator, BD, Basingstoke, UK) by rubbing the skin surface gently for 30 seconds. A sample of disinfected tissue was cultured both aerobically and anaerobically for 24 hours onto Columbia agar containing horse blood to confirm elimination of normal skin flora. Eight millimeter circular biopsies were taken from the main tissue sample using disposable biopsy punches (Integra Miltex, York, PA). In the center of these circular skin explants, a 3 mm diameter circular excisional artificial wound was created to a depth of 2 mm by a further punch biopsy. Explants were submerged into sterile 24-well Corning Costar cell culture plates (Sigma-Aldrich, Poole, UK), with each well containing 0.5 ml serum-free Williams E culture medium (ThermoFisher Scientific, Basingstoke, UK) supplemented with 1% (v/v) nonessential amino acid solution, 10 μl/ml insulin, 10 ng/ml hydrocortisone and 2 mmol L-glutamine. 27 Explants were maintained at 37 C in a stationary carbon dioxide (5%) incubator and were cultured for a minimum of 24 hours with daily medium change prior to use and were not utilized beyond 7 days to maintain explant viability. 28 Biofilm formation on an in vitro cell culture model
To generate a fresh supply of cells, a 50 ml centrifuge tube containing 25 ml Mueller Hinton Broth (supplier) was inoculated with a single colony of MSSA or PA and incubated at 37 C in a shaking incubator at 250 rpm overnight. Following this, a 50 ml centrifuge tube containing 25 ml Mueller Hinton Broth was inoculated with 200 μl of the overnight culture and incubated at 37 C in a shaking incubator at 250 rpm until the culture reached an optical density between 0.1 and 0.2. A 13 mm diameter Nunc™ Thermanox Coverslip (Thermo Scientific, Hampshire, UK) was used as the inert substrate for biofilm formation. Coverslips was placed with the treated surface facing upwards into a sterile 24 well Corning Costar cell culture plate and covered with 1 ml of MSSA or PA bacterial suspension. The plates were then incubated at 37 C in a stationary carbon dioxide (5%) incubator for up to 1 or 3 days. Appropriate controls inoculated with 1 ml sterile Mueller Hinton broth were also prepared and incubated for up to 1 or 3 days.
Biofilm formation on ex vivo cutaneous wound organ culture models PA bacterial suspensions for ex vivo explants were prepared in the same way as for in vitro biofilms, as described above. An 8 mm excisional cutaneous wound explant was used as the substrate for biofilm formation. The explant was placed with the wounded surface facing up into a sterile 24 well Corning Costar cell culture plate. PA bacterial suspension (1 ml at 0.1-0.2 OD) was pipetted into the well submerging the wound explant. The plates were then incubated at 37 C in a stationary carbon dioxide (5%) incubator for up to 3 days. Samples of inoculated tissue were cultured aerobically for 24 hours on Columbia agar containing horse blood to confirm mono-microbial biofilm formation at 3 days. Appropriate controls inoculated with 1 ml sterile Mueller Hinton broth were also prepared and incubated up to 3 days.
Biofilm exposure to ES and antibiotics
In vitro biofilms, days 1 and 3 MSSA and PA biofilms were subjected to the following:
ES
Biofilms were subjected to direct current (DC) ES waveform for 30 minutes at an electric field of 100 mV/mm. 28, 29 This electric field corresponds to the endogenous "current of injury" prevailing in cutaneous wound healing during initiation of granulation tissue, fibroplasia, wound contraction, and neovascularization. 30, 31 To deliver DC to the biofilm, coverslips were placed in the middle of a glass petri dish (radius: 25 mm) containing 2.5 ml Mueller Hinton broth. The current was received directly by the Ag-AgCl electrodes, which were dipped in Steinberg's saline solution (60 mM NaCl, 0.7 mM KCl, 0.8 mM MgSO 4 .7H 2 O, 0.3 mM CaNO 3 .4H 2 O, 1.4 mM Tris base maintained at pH 7.4). The inverted "U" shaped agar bridges filled with Steinberg's saline solution and gelled with 1% (w/v) agar (A/1080/48, Fisher Scientific, Loughborough, UK) carried the current from the solution into the petri dish. This set up for DC was developed to prevent the formation of air bubbles that would be generated if the electrodes were placed directly into the petri dish. The power supply (TTi EX752M) was set to constant current and the voltage adjusted until the Petri dish reached the desired field strength. A multimeter (TENMA model 72-7745, OH) was used to calculate voltage between the ends of the electrodes inside the ES chamber. This was performed every 15 minutes and was maintained consistently at 100 AE 3 mV/mm for the total duration of ES (30 minutes). Coverslips were then incubated in Mueller Hinton broth at 37 C in a stationary carbon dioxide (5%) incubator for 24 hours.
Antibiotic
Biofilms were subjected to ES using the same setup without any stimulation and then incubated in ciprofloxacin-HCl at 37 C in a stationary carbon dioxide (5%) incubator for 24 hours. A concentration of 10,000 mg/L was chosen, as preliminary work identified this concentration of ciprofloxacin resulted in less than 10% biofilm viability irrespective of species or time point (Supporting Information Figure S1 ).
Controls or nontreated
Biofilms were subjected to ES using the same setup without any stimulation and then incubated in Mueller Hinton broth at 37 C in a stationary carbon dioxide (5%) incubator for 24 hours. Ex vivo biofilms, day 3 PA biofilms were subjected to the following:
ES
Biofilms were subjected to DC ES waveform for 30 minutes at an electric field of 100 mV/mm as described above and were then incubated in Mueller Hinton broth at 37 C in a stationary carbon dioxide (5%) incubator for 24 hours.
Antibiotic
Biofilms were subjected to ES using the same setup without any stimulation and then incubated in ciprofloxacin at 37 C in a stationary carbon dioxide (5%) incubator for 24 hours. A concentration of 20 mg/L was chosen based on work conducted by Brunner et al. 32 which identified a single dose of 400 mg ciprofloxacin given intravenously led to a concentration of approximately 20 mg/L over a 24 hour period at a cantharis-induced blister site in healthy individuals.
ES + antibiotic
Biofilms were subjected to DC ES waveform for 30 minutes at an electric field of 100 mV/mm ES followed by incubation in ciprofloxacin (20 mg/L) at 37 C in a stationary carbon dioxide (5%) incubator for 24 hours.
Controls or nontreated
Biofilms were subjected to the same setup as for ES without any stimulation and then incubated in Mueller Hinton broth at 37 C in a stationary carbon dioxide (5%) incubator for 24 hours.
Biofilm visualization
Wound tissue explants were embedded in optical cutting temperature (OCT) compound (KP-CryoCompound, Klinipath, Duiven, The Netherlands) post-treatment, then snap-frozen in liquid nitrogen and stored at −80 C before cryosectioning. Ten micrometer sections were prepared with a cryostat microtome (OTF5000, Bright Instruments Ltd., UK). Each section was fixed in cold acetone for 10 minutes, which was then allowed to evaporate at room temperature. Slides were immersed in sterilized phosphate buffered saline (PBS) to remove residual OCT.
Live/dead staining
Coverslips were stained postexposure with FilmTracer LIVE/DEAD Biofilm Viability Kit (Invitrogen Molecular Probes, Carlsbad, CA) as per the manufacturer's instructions to visualize the effects of ES and/or antibiotics on viability and architecture. Images were collected on a Zeiss Axioimager.M2 upright microscope using a 40×/1.3 EC Planneofluar objective and captured using a Coolsnap HQ2 camera (Photometrics) through Micromanager software v1.4.23. Specific band pass filter sets for FITC and Texas Red were used to prevent bleed between channels. Images were then processed and analyzed using Fiji ImageJ (http://imagej.net/ Fiji/Downloads).
Hematoxylin and eosin staining
Tissue sections were stained for nuclei postexposure with hematoxylin (Sigma-Aldrich, Saint Louis, MO) and cytoplasm was counterstained with eosin (Sigma-Aldrich) in a Varistain™ 24-4 Automatic Slide Stainer (ThermoFisher Scientific, Basingstoke, UK). This involved fixation of sections for 2 minutes in 70% (v/v) industrial methylated spirits (IMS), followed by a 2 minute wash in water. Sections were stained for 2 minutes in hematoxylin Gills 2, and then in water. Tissue sections were then washed in 5% (v/v) acetic acid and dehydrated in graded IMS/ethanol (70%, 90%, and 100% [v/v]). Sections were counterstained with alcoholic eosin Y solution for 90 seconds followed by three 100% (v/v) ethanol washes. Finally, slides were clarified with xylene and then mounted in mounting media. Images were collected on an Olympus BX63 upright microscope using a 60×/1.42 PlanApo N and 100×/1.40 Uplan SApo objectives and captured and white-balanced using a DP80 camera (Olympus) in color mode through CellSens Dimension v1.16 (Olympus). Images were then processed and analyzed using Fiji ImageJ (http://imagej.net/Fiji/Downloads).
Gram-Twort staining
Tissue sections were stained postexposure with Gram-Twort for the demonstration of bacteria in tissue sections. Sections were brought down to water and stained in crystal violet solution followed by Gram's iodine for 3 minutes each. Tissue sections were then dried at 60 C and then differentiated in 2% (v/v) acetic acid alcohol for 13 minutes at 56 C. Sections were counterstained with Twort's stain for 5 minutes followed by dehydration in ethanol. Finally, slides were clarified with xylene and then mounted in mounting media. Images were collected on an Olympus BX63 upright microscope as described above.
DAPI + Concanavalin A staining
Tissue sections were stained postexposure with Concanavalin-A (Con-A) fluorescent stain and then incubated overnight at 4 C in the dark. The sections were then rinsed gently with PBS to remove excess stain. Sections were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI) by incubating for further 15 minutes at room temperature in the dark. Sections were finally rinsed gently with PBS. Images were collected on a Zeiss Axioimager.M2 upright microscope as described above.
Peptide nucleic acid-fluorescence in situ hybridization staining
Tissue sections were stained postexposure with a drop of a peptide nucleic acid-fluorescence in situ hybridization (PNA-FISH)-TexasRed conjugated to a specific universal bacterial (UniBac) 16S ribosomal RNA probe (AdvanDx, Woburn, MA). Samples were incubated for 90 minutes at 55 C. The coverslip was removed, and the slides were washed in warm washing buffer at 55 C (AdvanDx) for 30 minutes and then air dried in the dark. A drop of mounting medium was placed on top of the slide, which was then covered with a coverslip and air dried for 15 minutes. Images were collected on a Zeiss Axioimager.M2 upright microscope as described above.
Biofilm viability
Enumeration
Coverslips and wound tissue explants postexposure were submerged in 1 ml PBS and placed in an ultrasonic bath at 60 Hz and 60 W for 5 minutes with 30 seconds of vortexing either side to remove the remnants of the adherent biofilm. Colony-forming unit (CFU) assessment of the resultant bacteria was done in triplicate onto agar medium. These values were subsequently log transformed prior to statistical analyses.
Live/dead staining quantification
Definiens Tissue Studio software version 3.5.1 (Definiens, Munich, Germany) was used for analysis of LIVE/DEADstained coverslips postexposure and presented as viable bacteria/mm 2 . These values were subsequently log-transformed prior to statistical analyses.
Biofilm metabolic activity
Substrate in situ
The metabolic activity of biofilms grown on coverslips postexposure was assessed using the XTT cell proliferation assay. 33 A saturated solution was prepared from XTT reagent (Sigma-Aldrich, Poole, UK) in 1× PBS at a concentration of 0.5 g/L. To activate XTT, 100 μl 1 mM menadione (Sigma-Aldrich) was added to every 10 ml XTT solution used. Activated XTT (400 μl) was added to each well, incubated for 2 hours at 37 C in the dark and the color change measured using a POLARStar Omega spectrophotometer (BMG Labtech, Ortenberg, Germany) at an absorbance of 490 and 630 nm. Results were processed using Omega software (BMG Labtech) and 630 mn absorbance values subtracted from the 490 nm.
Biofilms detached from substrate
The metabolic activity of biofilms grown on coverslips and wound tissue explants, then detached postexposure, were also assessed using the XTT cell proliferation assay. To separate biofilms, coverslips, or explants were submerged in 1 ml PBS and placed in an ultrasonic bath at 60 Hz and 60 W for 5 minutes with 30 seconds of vortexing pre-and post-sonication. Biofilm material was sedimented by centrifugation at 12,000×g for 5 minutes. A saturated solution of XTT was prepared and activated as described above. PBS was removed and 400 μl/well-activated XTT solution was added. Samples were vortexed for 30 seconds to resuspend the biofilm and subsequently processed as described above.
Biofilm biomass
Biofilm dsDNA, representing biomass, was extracted by separating the biofilm from its respective substrate and measured using the fluorescent nucleic acid Quant-iT PicoGreen dsDNA reagent (Molecular Probes, Inc.). Nucleic acids were extracted from biofilms using the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA), according to the manufacturer's recommendations. Nucleic acid extracts and the PicoGreen reagent were mixed thoroughly before fluorometric analysis at 492 nm (BMG Labtech). Lambda DNA included in the kit was used to construct the standard curve (concentration range 0-1,000 ng/ml) according to the manufacturer's instructions.
Gas chromatography-mass spectrometry
Precision thread headspace vials (20 ml, Fisher Scientific, Loughborough, UK) sealed with universal magnetic screw caps with PTFE/butyl penetrable septa (Fisher Scientific) were used as they were shown to be optimum for the containment of VOCs for headspace sampling and GCMS analysis.
GCMS analyses were performed using an Agilent 5977A MSD mass spectrometer (Agilent Technologies, Santa Clara, CA) linked to GC (Agilent 7890B GC system, Agilent Technologies) which was equipped with an autosampler (PAL RSI 85 autosampler system, Agilent Technologies). Postexposure coverslips and wound tissue explants were sealed in headspace vials for 24 hours at 37 C prior to headspace sampling which consisted of agitating at 37 C for 5 minutes. A headspace gas sample (1 ml) was collected using an Agilent gas-tight syringe Chromatograms were processed with MassHunter qualitative analysis software (Agilent Technologies) prior to further statistical analyses. Chromatograms were processed by introducing a 2 minutes solvent delay, noise removal, and by comparing each inoculated sample to its corresponding time point control. Peaks based on retention times unique to inoculated samples underwent baseline subtraction and the resulting mass spectra were tentatively identified based on forward and reverse match searches of the National Institute of Standards and Technology library. The area of each unique chromatographic peak was calculated to provide relative abundances. A peak common to all samples and controls was identified and the area of each unique chromatographic peak was normalized to this common peak to account for GCMS variations over the sampling duration. A value of 1 was added to all normalized peak areas and subsequently log transformed prior to statistical analyses.
Statistical analysis
Continuous data were summarized as the mean AE 95% confidence intervals. A generalized estimating equations model with pairwise Bonferroni corrections was used for all the biofilm parameters measured: viability (CFU assessment and live/dead quantification), metabolic activity (XTT assay), biomass (PICO green dsDNA assay), and relative abundances of VOCs. Spearman's correlation coefficient was calculated to assess the association among biofilm viability, metabolism, or biomass and relative abundances of VOCs. 34 A p-value of <0.05 was considered statistically significant. Statistical analyses were performed using SPSS for Windows version 22.0 (SPSS, IBM, Armonk, NY) and graphical representation using GraphPad Prism 7 (GraphPad Software, La Jolla, CA).
Ethics statement
Written informed consent was obtained from patients for tissue samples. Permission was granted by NHS National Research Ethics Service.
RESULTS
ES reduces viability of MSSA and PA biofilms in vitro
Viability, as determined by enumeration and fluorescence quantification, was significantly reduced in methicillin sensitive S. aureus (MSSA) biofilms exposed to ES at day 1 (p < 0.05; Figure 2A and B; Supporting Information Table S1 ). Visualization confirmed reduced day 1 MSSA viability, with biofilm disruption appearing as sparse patches of viable colonies ( Figure 2F ). MSSA biofilms matured by day 3 as shown by the increasing separation of areas of heavily concentrated viable bacteria ( Figure 2F ), with some highly dense areas suggesting the presence of foci of dissemination, typical of mature biofilms. Biofilms exposed to ES appeared with fewer concentrated nodules; however, viability was not significantly reduced (p > 0.05; Figure 2A and B). There was a significant reduction in viability of P. aeruginosa (PA) biofilms exposed to ES at days 1 and 3 (p < 0.05; Figure 3A and B). This was confirmed visually with a reduction in viable cells (green stained) and a sparsity of colonies ( Figure 3F ).
ES decreases metabolic activity and biomass of MSSA and PA biofilms in vitro
The metabolic activity of biofilms was determined using the XTT reduction assay either with the coverslip in situ or with detached biofilms. Metabolic activity of MSSA biofilms exposed to ES was significantly reduced by day 3 when assessed in situ (p < 0.05; Figure 2C ). Moreover, metabolic activity was significantly reduced at days 1 and 3 in these biofilms were detached from the substrate (p < 0.05; Figure 2D ). ES-treated PA biofilms on days 1 and 3 showed significant reduced metabolic activity irrespective of the assay method used (p < 0.05; Figure 3C and D). The trends of metabolic activity reduction in ES exposed MSSA and PA biofilms was the same in both techniques. The removal of the biofilm from the substrate followed by XTT reduction assay may provide a more accurate representation of its metabolic activity, as the XTT compound is able to better penetrate through all areas of the biofilm which may not be possible in biofilms left attached to the substrate. Therefore, further metabolic activity quantification in the ex vivo model was conducted using this latter protocol. Biomass was significantly reduced in day 3 MSSA and PA biofilms exposed to ES (p < 0.05; Figures 2E and 3E ). ES had no significant effect on the biomass of early (day 1) MSSA and PA biofilms.
ES effects PA biofilm viability, metabolic activity, and biomass in a clinically relevant ex vivo model Viability, metabolic activity, and biomass were significantly reduced in ex vivo PA biofilms exposed to ES, antibiotic and in combination (ES + Antibiotic) compared to untreated controls (p < 0.05; Figure 4 ). PA biofilm viability (p < 0.05), metabolic activity (p < 0.05), and biomass (p < 0.05) were all reduced significantly when exposed to antibiotics or antibiotics plus ES as compared to ES exposure alone. Biofilm visualization confirmed the above findings with biofilm thickness reduced following ES exposure compared to controls but with a greater reduction in biofilms exposed to antibiotic alone or in combination with ES ( Figure 5A-E) . This pattern of reduced biomass was confirmed visually with concanavalin A and in in situ fluorescence hybridization (FISH)-stained sections ( Figure 5E and F). Exposure to ES followed by antibiotic treatment had no significant impact on PA biofilm viability, metabolic activity, or biomass when compared to antibiotic only treated biofilms (p > 0.05).
VOC biomarker variations allow monitoring of response to treatment
VOC profiling by GCMS of 108 MSSA and PA in vitro biofilms exposed to ES, antibiotics, or no treatment was undertaken to identify potential biomarkers that could be used to monitor response to treatment. Butanedione and acetic acid ethenyl ester were only identified in MSSA biofilms exposed to ciprofloxacin (p < 0.05; Figure 6A and B). The relative abundances of 2-methyl-1-propanol and 3-methyl-1-butanol were significantly reduced in antibiotic-exposed MSSA biofilms on days 1 and 3 compared to those exposed to ES or untreated, control biofilms (p < 0.05). The relative abundance of 2-methyl-1-propanol was also significantly reduced in ES-exposed MSSA biofilms on day 3 compared to controls (p < 0.05).
The relative abundance of hydrogen cyanide, 5-methyl-2-hexanamine, 5-methyl-2-heptanamine, 1-undecene, 3-methyl-1-butanol, and 2-nonanone was significantly reduced in PA biofilms (on both days 1 and 3) exposed to antibiotic compared to those exposed to ES or untreated, control biofilms (p < 0.05; Figure 6C and D). Hydrogen cyanide, 5-methyl-2-hexanamine, 1-undecene, 3-methyl-1-butanol, and 2-nonanone were significantly reduced in ES-exposed day 3 PA biofilms compared to untreated controls (p < 0.05).
The application of VOC biomarkers in treatment response monitoring in a clinically relevant ex vivo model VOC profiling by GCMS of 72 ex vivo PA biofilms exposed to ES, antibiotics, or in combination (ES + Antibiotic) revealed five VOCs unique to PA biofilms. The relative abundance of hydrogen cyanide, 5-methyl-2-hexanamine, 5-methyl-2-heptanamine, and 1-undecene was significantly reduced in antibioticexposed PA biofilms alone or in combination with ES (p < 0.05; Figure 6E ). Levels of 5-methyl-2-hexanamine, 5-methyl-2-heptanamine, 1-undecene, and 2-nonanone were significantly reduced in PA biofilms exposed to ES only (p < 0.05).
VOC biomarkers in MSSA and PA biofilms correlated with viability, metabolic activity, and biomass MSSA production of 2-methyl-1-propanol correlated positively with biofilm viability (R = 0.93, p < 0.05: Figure 7A and B), biomass (R = 0.97; p < 0.05; Figure 7C ), and metabolic activity (R = 0.93; p < 0.05; Figure 7D) ; meanwhile PA production of 3-methyl-1-butanol positively correlated with biofilm biomass (R = 0.93; p < 0.05; Figure 7E ). Visualization and comparison of viability, metabolic activity, and biomass of in vitro MSSA biofilms following exposure to antibiotics or ES. Biofilm viability was determined by (A) CFU assessment or (B) SYTO 9 quantification using Definiens Tissue Studio software. Metabolic activity was determined by the XTT reduction assay with (C) the substrate (i.e., coverslip) in situ or (D) the biofilm separated from the substrate. (E) Biomass was determined by Quant-iT PicoGreen dsDNA reagent assay. Mean AE 95% confidence intervals (n = 6), *p < 0.05, **p < 0.01, ***p < 0.001, as determined by generalized estimating equation model with accompanying Bonferroni post hoc analyses. Means were compared at each time point to the control treatment. (F) LIVE/DEAD staining. Viable bacteria are stained green with the nucleic acid stain SYTO 9 and extracellular DNA or dead bacteria are stained red with the nucleic acid stain propidium iodide. Scale bar: 10 μm. MSSA, methicillin sensitive Staphylococcus aureus; ES, electrical stimulation. [Color figure can be viewed at wileyonlinelibrary.com] Figure 3 . Visualization and comparison of viability, metabolic activity, and biomass of in vitro PA biofilms following exposure to antibiotics or ES. Biofilm viability was determined by (A) CFU assessment or (B) SYTO 9 quantification using Definiens Tissue Studio software. Metabolic activity was determined by the XTT reduction assay with (C) the substrate (i.e., coverslip) in situ or (D) the biofilm separated from substrate. (E) Biomass was determined by Quant-iT PicoGreen dsDNA reagent assay. Mean AE 95% confidence intervals (n = 6), *p < 0.05, **p < 0.01, ***p < 0.001, as determined by generalized estimating equation model with accompanying Bonferroni post hoc analyses. Means were compared at each time point to the control treatment. (F) LIVE/DEAD staining. Viable bacteria are stained green with the nucleic acid stain SYTO 9 and extracellular DNA or dead bacteria are stained red with the nucleic acid stain propidium iodide. Scale bar: 10 μm. PA, Pseudomonas aeruginosa; ES, electrical stimulation. [Color figure can be viewed at wileyonlinelibrary.com]
DISCUSSION
Biofilms present in chronic wounds account for up to 60% of infections 1 and in SSIs, where the prevalence is even higher. 2 Biofilms cause chronic infections due to increased tolerance to antibiotics and resistance against the body's immune system. 35 Therefore, this study attempted to address this clinical concern by determining whether ES could be useful in the management of wound biofilms. Endogenous direct current (DC) electric fields are fundamental components of development and regeneration, which suggest a critical role in wound healing. 36 DC, a monophasic electrical waveform, was used to successfully reduce MSSA and PA biofilm viability, metabolic activity, and biomass in vitro. Its application to mature PA biofilms in a human ex vivo excisional cutaneous wound model confirmed a reduction in all these parameters compared to untreated controls. We identified that ES reduced biomass; this corroborates previous findings which found ES reduced biofilm attachment and adherence, key factors in biofilm formation and development. 37 While the use of ES in wound care management is well established, 38 we did not identify any previous studies assessing the impact of ES on wound biofilms in a human ex vivo model. Investigations of ES against biofilms in vivo are also sparse, with only six studies to date having assessed the effect of ES on biofilms, with the majority showing positive outcomes [39] [40] [41] [42] [43] [44] ; however, none of these studies investigated the direct effect of ES on cutaneous wound bacterial biofilms.
ES, however, was not as effective in reducing biofilm compared to ciprofloxacin in both in vitro and ex vivo models. The effectiveness of ciprofloxacin was not unexpected in vitro as the concentration used reduced biofilm metabolic activity by greater than 90%. This high dose was chosen as a positive control to allow effective comparisons between changes to relative abundances of VOCs in biofilms exposed to ciprofloxacin which were expected to have a significant anti-biofilm effect compared to clinically useable ES parameters, where the anti-biofilm effect was unknown. In the ex vivo model, despite the use of a clinically relatable concentration of ciprofloxacin being used 32 ; it was still more effective against PA biofilms compared to ES exposure. Moreover, only a single dose of either treatment was investigated. With the increasing concern of antibiotic resistance, prolonged or repeated ES treatment may have a role in anti-biofilm management. Further studies to determine if repeated or prolonged ES use could be as effective or could complement and perhaps even replace antibiotic treatment are necessary. Also, the use of ES as an alternative therapy choice may be more relevant against antibiotic-resistant bacterial strains; further experimental work, including resistant strains is necessary to clarify the circumstances where ES may be most beneficial.
ES may increase the efficacy of antibiotics, a concept termed the "bioelectric effect"; and this has been shown in the majority of studies to date which have used DC. 45 Many have shown an enhancing effect of ES on the efficacy of antimicrobials in vitro 46 ,47 although we were not able to demonstrate this in vitro or ex vivo in the present study. However, we only assessed the bioelectric effect against one species at a single time point with the use of a single antibiotic agent at a high, fixed concentration. Del Pozo et al. proposed that the bioelectric effect is not universal across all microorganisms and antimicrobials and its use should probably be selective. 48 Antibiotic-specific bioelectric effects have been shown previously 49 where certain antibiotics were enhanced with the addition of ES, whereas others had no increased efficacy against Pseudomonas biofilms. Variations in intensity of the currents can also enhance the bioelectric effect 46 ; however, caution must be applied as there will be limitations on the ES parameters deemed safe for use in the clinical setting. The applied electric field we used corresponds to the endogenous "current of injury" which is the lateral electrical field that is generated through the wound following an injury to the skin, thought to be significant in initiating repair 50 and deemed safe in the clinical environment. 30, 31 A major limitation when investigating wound biofilm diagnostic and treatment methods is the availability of appropriate skin wound biofilm models. 7 The porcine ex vivo wound model is most commonly used for investigating biofilm formation and assessing therapeutics. [19] [20] [21] [22] 51 However, porcine skin is not identical to human skin, yet there are very few studies utilizing human skin as a substrate for biofilm formation. 52, 53 We have previously established the formation of common cutaneous wound pathogenic bacterial biofilms on a human ex vivo excisional cutaneous wound model. 25 Here, we successfully used this human cutaneous biofilm wound model to assess the efficacy of ES against biofilms and to determine if it was possible to use VOC biomarkers in monitoring treatment response.
This study demonstrated the application of VOC biomarkers to monitor bacterial biofilm response to treatment with potential clinical use. Current monitoring of wound infection response to treatment involves a combination of clinical indicators which are subjective and microbial sampling for laboratory culturing and sequencing, which are limited by time and accuracy. 5, 54 The use of VOCs and its application in point of care testing, such as electronic nose technologies in wound infection diagnoses, have been investigated and discussed previously. 55, 56 As with the use of VOC profiles in the diagnosis of lung disease, their use as potential markers in monitoring treatment response have been more robustly investigated, 8, 57 compared to their use in monitoring wound infection response to treatment, which is limited. 58 Here, we showed dynamic changes in VOC profiles in response to antibiotic-or ES-treated biofilms in vitro and confirmed these findings in our clinically relevant human ex vivo wound biofilm model. These results imply that detection of VOCs and their various profiles can be harnessed for point of care testing which would ameliorate wound infection diagnosis and treatment. Of interest was the detection of butanedione and acetic acid ethenyl ester in ciprofloxacin-treated MSSA biofilms and these two VOCs, could be breakdown products of MSSA biofilms. However, these findings are exploratory and further experimental work including multiple time points and bacterial strains are necessary before firm conclusions can be drawn about their usefulness.
This study has a number of limitations. Only two bacterial strains were used as mono-cultures in vitro and one in the ex vivo model, while most chronic wounds comprise poly-microbial biofilms, 1 although single pathogen wound infections do occur. A natural progression of this work is to investigate the impact of ES and VOC detection in Gram positive and poly-microbial biofilms using our ex vivo model. The ex vivo model developed more closely portrays a human skin wound than our or other published in vitro models; but direct translation of the results to the clinical setting should be met with caution. Although we found a statistically significant reduction (greater than 60%) in bacterial viability of biofilms exposed to ES, this is not a clinically significant reduction in terms of chronic wound healing, and therefore, human trials are necessary to validate our findings. While certain differences between controls and treatment modalities were statistically significant, the absolute reductions were small and may not be clinically significant. In addition to our previously published model, 59 other methods of explant inoculation, such as surface and intradermal delivery have also been validated. 20, 53 The identification of the compounds using the mass spectral library must be interpreted with caution as they have not been confirmed using analytical standards. And finally, only DC ES was used; several different waveforms and delivery methods of ES are available in wound management. 38, 60 In conclusion, we have successfully utilized a human cutaneous wound biofilm model to assess VOCs as potential biomarkers and used ES as an alternative to antimicrobial treatment, showing the potential of both for chronic wound care. This study provides a platform for future work investigating the use of VOC biomarkers as diagnostic and monitoring tools in wound infections which could ultimately lead to improved clinical outcomes.
